2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow palbociclib: new trials by email Literature Review of palbociclib trials Research Report on palbociclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab - Metastatic Breast Cancer | Phase 3 | Terminated | SOLTI Breast Cancer Research Group | 61 | 2022-03-28 | 2026-06-25 |
| Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer Amcenestrant-matching placebo, SAR439859, Palbociclib - Breast Cancer | Phase 3 | Terminated | Sanofi | 1068 | 2020-10-14 | 2025-09-11 |
Breast Neoplasms (2)
SOLTI Breast Cancer Research Group (1) · Sanofi (1)
Portugal (2) · Spain (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · Finland (1) · France (1)
Aleix Prat, MD (1) · Dan G Stover, MD (1) · Lisa A Carey, MD (1)